Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- The Mysterious Case Of the Missing Fingerprints (CME/CE)
- 'Cannabis Alters Human DNA' - New Study
- New Molecular Pathway For Targeting Cancer, Disease Discovered By UCLA Researchers
- The Cancer Institute Of New Jersey Network Of Hospitals At The Forefront Of Testing New Nationwide Data Reporting System
- Following Cancer Diagnosis, More Women Choosing To Remove Healthy Breast
- Removing Arsenic From Drinking Water: Guanajuato Will Be First To Try Rice's 'Nanorust'
- Diffusion Tensor Imaging Increases Ability To Remove Benign Tumors In Children Minimizes Postoperative Neurological Problems
- Government Of Canada Approves A New Source Of Medical Isotopes
- Non-Communicable Diseases - The Next Health Tsunami
- Investigational Drug Shows Promise As Treatment For Overexposure To Common Cancer Chemotherapy
Prescription Cancer Drugs
Polyomavirus Infection In Merkel Cell Carcinoma Is Associated With Better Outcomes
Posted by: admin in Prescription Cancer Drugs on June 23rd, 2009
A polyomavirus known as MCPyV is associated with clinical outcomes, including fewer metastases and better survival, in patients with a rare form of skin cancer called Merkel cell carcinoma, according to a new study published online June 17 in the JNCI.
Integration of the Merkel cell carcinoma polyomavirus (MCPyV) genome into the tumor genome was recently found to be frequent in skin cancers, but the clinical consequences of MVPyV genomic integration was unclear.
To examine the consequences of viral DNA integration, Heikki Joensuu, M.D., of the Department of Oncology at Helsinki University Central Hospital, and colleagues, conducted histopathologic and molecular biological analyses of tumor tissue and DNA from 109 Finnish patients who were diagnosed with Merkel cell carcinoma from 1979 to 2004.
Approximately 50% of the tumors were positive for MCPyV DNA. These cancers tended to be located in a limb, to have less frequent nodal or distant metastases at the time of diagnosis, and to be associated with better survival compared with MCPyV DNA-negative cancers.
“Identification of MCPyV as a contributing factor to the pathogenesis of Merkel cell carcinoma might provide novel choices for future therapeutic strategies,” the authors write.
In an accompanying editorial, James A. DeCaprio, M.D., of the Dana-Farber Cancer Institute in Boston, points out parallels between MCPyV infection in Merkel cell carcinoma and human papillomavirus infection in head and neck cancers, suggesting reasons that the presence of these viruses would predict a better prognosis.
“Perhaps expression of the viral oncogenes can induce or promote the development of cancers that have fewer host cell chromosomal abnormalities, which may result in tumors with simpler genomic abnormalities,” the editorialist writes. “Alternatively, the viral oncogenes may specifically perturb host signaling pathways, including immune surveillance, that render them less aggressive or lethal.”
Author:
Joensuu Heikki
Source:
Steve Graff
Journal of the National Cancer Institute
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.